EXPO trades 22.6% below Wall Street's consensus target of $75.00.
Last 12 months price action with 12-month analyst target path
The base valuation assumes EXPO achieves its forward estimates and maintains a stable P/E multiple of 29.8x. This scenario reflects the blended consensus of 8 Wall Street analysts, balancing both positive catalysts and macroeconomic headwinds over the next 12 months.
As of July 7, 2026, Exponent, Inc. (EXPO) has a Wall Street consensus price target of $75.00, based on estimates from 8 covering analysts. With the stock currently trading at $61.18, this represents a potential upside of +22.6%. The company has a market capitalization of $2.97B.
Analyst price targets range from a low of $75.00 to a high of $75.00, representing a 0% spread in expectations. The median target of $75.00 aligns closely with the consensus average. The tight target dispersion indicates high conviction among analysts.
The current analyst consensus rating is Buy, with 6 analysts rating the stock as a Buy or Strong Buy,2 rating it Hold, and 0 rating it Sell or Strong Sell. This overwhelmingly bullish sentiment suggests analysts see significant catalysts for upside ahead.
From a valuation perspective, EXPO trades at a trailing P/E of 29.6x and forward P/E of 29.8x. The forward PEG ratio of 5.00 reflects a premium valuation. Analysts expect EPS to grow -5.4% over the next year.
Our proprietary valuation model, which blends historical multiples with forward estimates, suggests a base-case price target of $66.76, with bear and bull scenarios of $42.06 and $87.97 respectively. Model confidence stands at 47/100, suggesting limited visibility into future performance.
| Company | Market Cap | Price | Target | Upside Potential | Rating | Fwd P/E | Analysts |
|---|---|---|---|---|---|---|---|
ICFIICF International, Inc. | $1.4B | $74.85 | $90.00 | +20.2% | Buy | 10.7x | 13 |
CRAICRA International, Inc. | $969M | $149.95 | $194.00 | +29.4% | Buy | 18.2x | 1 |
HCIHCI Group, Inc. | $2.4B | $181.72 | $126.50 | -30.4% | Buy | 10.4x | 14 |
FORRForrester Research, Inc. | $185M | $9.63 | — | — | Hold | 12.6x | 4 |
FCNFTI Consulting, Inc. | $4.7B | $155.69 | $174.50 | +12.1% | Buy | 16.8x | 13 |
VRSKVerisk Analytics, Inc. | $24.6B | $187.79 | $226.11 | +20.4% | Hold | 24.5x | 25 |
EFXEquifax Inc. | $20.7B | $171.94 | $222.18 | +29.2% | Buy | 20.0x | 34 |
ACNAccenture plc | $83.8B | $136.96 | $198.06 | +44.6% | Buy | 9.9x | 53 |
BAHBooz Allen Hamilton Holding Corporation | $7.5B | $62.31 | $89.50 | +43.6% | Buy | 10.3x | 21 |
SAICScience Applications International Corporation | $4.8B | $114.70 | $111.75 | -2.6% | Hold | 11.4x | 18 |
Quick answers to the most common questions about buying EXPO stock.
The consensus Wall Street price target for EXPO is $75, representing 22.6% upside from the current price of $61.18. With 8 analysts covering the stock, this strong upside suggests significant value not yet reflected in today's share price.
EXPO has a consensus rating of "Buy" based on 8 Wall Street analysts. The rating breakdown is predominantly bullish, with 6 Buy/Strong Buy ratings. The consensus 12-month price target of $75 implies 22.6% upside from current levels.
EXPO trades at a forward P/E of 29.7684x, representing a moderate valuation. With analysts targeting $75 (22.6% implied move), the stock appears reasonably valued with upside.
The most bullish Wall Street analyst has a price target of $75 for EXPO, while the most conservative target is $75. The consensus of $75 represents the median expectation. Our quantitative valuation model projects a bull case target of $88 based on optimistic growth and margin assumptions. These targets typically reflect 12-month expectations.
EXPO is moderately covered, with 8 analysts providing price targets and ratings. Of these, 0 have Strong Buy ratings, 6 have Buy ratings, 2 recommend Hold, and 0 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.
The 12-month EXPO stock forecast based on 8 Wall Street analysts shows a consensus price target of $75, with estimates ranging from $75 (bear case) to $75 (bull case). The median consensus rating is "Buy". Our proprietary valuation model produces a base case fair value of $67, with bear/bull scenarios of $42/$88.
Our quantitative valuation model calculates EXPO's fair value at $67 (base case), with a bear case of $42 and bull case of $88. The model uses discounted cash flow analysis, historical growth rates, and margin mean-reversion to project FY+2 earnings, then applies an appropriate P/E multiple. The model confidence score is 47/100.
EXPO trades at a forward P/E ratio of 29.8x based on next-twelve-months earnings estimates compared to a trailing P/E of 29.6x. The higher forward P/E suggests near-term earnings pressure. A forward P/E is useful for comparing valuations when earnings are expected to change significantly.
Wall Street analysts are very optimistic on EXPO, with a "Buy" consensus rating and $75 price target (22.6% upside). 6 of 8 analysts rate it Buy or Strong Buy. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.
EXPO analyst price targets range from $75 to $75, a 0% tight range reflecting strong analyst consensus. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $75 consensus represents the middle ground. Our model's $42-$88 range provides an independent fundamental perspective.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.